CLARENCE, N.Y.--(BUSINESS WIRE)--Mar. 8, 2012--
Greatbatch, Inc. (NYSE: GB) - In support of further advancing its
medical device and systems strategy, Greatbatch, Inc. today announced
the appointment of Michael Dinkins as senior vice president and chief
financial officer (CFO) and Daniel R. Kaiser, Ph.D., as vice president
and chief technology officer (CTO).
CFO and Related Appointments
Mr. Dinkins has compiled nearly two decades of senior leadership roles
with publicly-traded organizations. He was most recently the executive
vice president and CFO for USI Holdings Corporation, the insurance and
risk management intermediary. He previously served as the executive vice
president and CFO of Hilb Rogal & Hobbs Co. and as vice president,
Global Control & Reengineering for Guidant Corporation. He was elected
to the Greatbatch Board of Directors in 2008, and will resign the seat
when he assumes the CFO position.
“Taking into account our strong business performance coupled with even
greater opportunity on the horizon, it’s the ideal time to further
strengthen our talented financial leadership group,” said Greatbatch
President and Chief Executive Officer, Thomas J. Hook. “Mike has
provided consistent leadership and guidance as a member of our Board. We
will now be able to more fully leverage his broad management skills and
significant financial experience as an Executive Leadership Team member.”
Tom Mazza, who has served as the company’s chief financial officer since
2005, will transition to a role as vice president and corporate
controller, and principal accounting officer. “We couldn’t have grown
the company to its present state without the leadership of Tom, who will
continue to be a key member of our leadership team,” Hook added. “In his
new role, Tom will lend his insights, financial expertise and industry
knowledge to support our long term corporate strategies.”
“Considering that the company is coming off a very good year with strong
results and positive momentum, it’s an opportune time to bolster our
team,” said Mr. Mazza. “We’re so fortunate to be joined by an executive
of Mike’s caliber, and I look forward to working closely with him
through the transition and in my new role.”
Marco Benedetti, currently corporate controller and principal accounting
officer, will transition to the role of vice president responsible for
financial planning & analysis and investor relations functions for the
company.
CTO Appointment
Dr. Kaiser will immediately assume the company’s newly-created CTO
position, where he will serve as the leader of QiG Group – Greatbatch’s
research and development subsidiary – and also provide strategic
guidance and technical leadership to the Greatbatch Medical and
Electrochem businesses.
Since joining Greatbatch in 2008, Dr. Kaiser has taken on increasing
responsibility in a number of key leadership roles in product planning,
marketing, and development. His most recent role included leading the
product development, design assurance, and regulatory affairs for QiG
Group’s Cardiovascular Portfolio. Prior to joining Greatbatch, he held
positions of progressive responsibility within established medical
device companies such as Medtronic, Inc. and Guidant Corporation, led
the research efforts of a large Cardiology private practice at the St.
Paul Heart Clinic, and fostered research and innovation at the academic
level with over 23 publications as an adjunct assistant professor at the
University of Minnesota. Dr. Kaiser, who received a Bachelors of Science
in Electrical Engineering from the University of Wisconsin – Madison,
and a MS and Ph.D. in Biophysical Sciences and Medical Physics from the
University of Minnesota, is the inventor or co-inventor of 10 granted
and pending patents.
“Dan has demonstrated exceptional performance in navigating our
cardiovascular portfolio, including spearheading five product approvals.
His leadership of QiG Group will be essential as we drive the
commercialization phase of our medical device and systems strategy,”
said Mr. Hook.
QiG Group was previously led by Mr. Hook, under whose leadership it has
grown to more than 150 highly skilled research and development
Associates.
About Greatbatch
Greatbatch, Inc. (NYSE: GB) provides top-quality technologies to
industries that depend on reliable, long-lasting performance through its
brands Greatbatch Medical, Electrochem and QiG Group. Greatbatch Medical
develops and manufactures critical medical device technologies for the
cardiac, neurology, vascular and orthopaedic markets. Electrochem
designs and manufactures battery and wireless sensing technologies for
high-end niche applications in the energy, military, portable medical,
and other markets. The QiG Group empowers the design and development of
new medical devices for our core markets. Additional information about
the Company is available at www.greatbatch.com.
Source: Greatbatch, Inc.
Greatbatch, Inc.
Investor Relations:
Marco Benedetti,
716-759-5856
mbenedetti@greatbatch.com
or
Media:
Christopher
Knospe, 716-759-5727
cknospe@greatbatch.com